Sign in
Active, not recruitingNo phase

Autus Valve Pivotal Study

Key facts

Who runs it
Edwards Lifesciences
Where
Ann Arbor, Atlanta, Aurora, Boston, Chicago, Columbus, Durham, Los Angeles, New York, Philadelphia, Salt Lake City, and Seattle, United StatesSee the 12 sites
Trial code
Status
Active, not recruiting
People taking part
62 people enrolled
Started
5 Feb 2024
Expected to end
5 Feb 2036
Type of study
Interventional
Treatments tested
  • Pulmonary Valve Replacement Surgery
Record updated
20 October 2026

Who can take part

Age
18 months to 16 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study
  • Age 18 months to 16 years
  • Male or female
  • Subject has a native or repaired right ventricular outflow tract
  • Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon)
  • Subject has at least one of the following echocardiographic findings:; Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg); Moderate or greater pulmonary regurgitation; Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation
  • Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter)
  • Subject and parent/legal representative, where appropriate, are willing to provide informed written consent
  • Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits

Who cannot take part

  • Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses
  • Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening
  • Candidates will be excluded from the study if any of the following conditions are met:
  • Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg)
  • Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics)
  • Subject has active endocarditis or a history of infective endocarditis
  • Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs
  • Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes
  • Subject needs emergency cardiac or vascular surgery or intervention
  • Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease
  • Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
  • Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L)
  • Subject has thrombocytopenia (defined as platelet count <50 x 103/µL
  • Subject requires valve replacement in a non-pulmonary position
  • Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years)
  • Subject has pulmonary atresia and major aortopulmonary collaterals
  • Subject has significant peripheral pulmonary artery stenosis
  • Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years
  • Subject or parent/legal representative refuses blood transfusions
  • Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures

Where in United States

  • University of Michigan/Mott Children's HospitalAnn Arbor, United States
  • Children's Healthcare of AtlantaAtlanta, United States
  • Children's Hospital ColoradoAurora, United States
  • Boston Children's HospitalBoston, United States
  • Ann and Robert H. Lurie Children's Hospital of ChicagoChicago, United States
  • Nationwide Children's HospitalColumbus, United States
  • Duke UniversityDurham, United States
  • Children's Hospital Los AngelesLos Angeles, United States
  • Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's HospitalNew York, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • University of Utah - Intermountain Primary Children's HospitalSalt Lake City, United States
  • Seattle Children's HospitalSeattle, United States

About the trial

What the trial wants to find out

Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.

Read full original descriptionShow less

The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.

The group in the trial

  • Autus Valve ArmTreatment being tested

    Pulmonary Valve Replacement Surgery with the Autus Valve

    Treatment: Pulmonary Valve Replacement Surgery

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Autus Size-Adjustable Valve for Surgical Pulmonary Valve Replacement Pivotal Study
Record updated
20 October 2026